Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 9, 2009, Pages 564-569

  Niazi, Mohammad ^a   Andersson, T ^a   Naucler E ^a   Sundin, M ^a   Naesdal J ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Acetylsalicylic acid; Esomeprazole; Interaction; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; ESOMEPRAZOLE; ANTIULCER AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE;

ABDOMINAL PAIN; ADULT; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; GUM ITCHINESS; HEMATOMA; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STEADY STATE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; DRUG INTERACTION; MIDDLE AGED;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; AREA UNDER CURVE; ASPIRIN; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; YOUNG ADULT;

EID: 70349944531     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47564     Document Type: Article

References (10)

1. Abelo A, Andersson TB, Antonsson M et al. Stereo-selective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000; 28: 966-972.
2. Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001; 344: 967-973.
3. Clappers N, Brouwer MA, Verheugt FW. Antiplatelet treatment for coronary heart disease. Heart. 2007; 93: 258-265.
4. Iñarrea P, Esteva F, Cornudella R et al. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol. 2000; 35: 242-246.
5. Laheij RJ, Jansen JB, Verbeek AL et al. Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischemic heart disease. Aliment Pharmacol Ther. 2001; 15: 1055-1059.
6. Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002; 346: 2033-2038.
7. Lanas A, Rodrigo L, Marquez JL et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol. 2003; 38: 693-700.
8. Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB et al. Interaction of omeprazole with enteric-coated salicylate tablets. Int J Clin Pharmacol Ther. 1998; 36: 549-553.
9. van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol. 2008; 22: 209-224.
10. Yeomans N, Lanas A, Labenz J et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008; 103: 2465-2473.